U. MICHIGAN (US) — A drug used as an antidepressant since the 1960s can essentially reverse the effects of sickle cell disease, according to a new finding made in mice and human red blood cells.
Scientists made the discovery about the drug tranylcypromine, or TCP, after more than three decades studying the basic biology of the condition.
Their findings pave the way for a clinical trial now being planned for adult patients who have the life-threatening condition. The discovery may also lead to other treatments for the disease, which leads misshapen red blood cells to cause vascular damage and premature death.
But it is too soon for the drug to be used in routine treatment of sickle cell anemia, an inherited genetic disease that affects tens of thousands of Americans and millions of others worldwide.
In the new paper, published in the journal Nature Medicine, researchers describe a painstaking effort to test TCP’s effect on the body’s production of a particular form of hemoglobin—the key protein that allows red blood cells to carry oxygen.
TCP acts on a molecule inside red blood cells called LSD1, which is involved in blocking the production of the fetal form of hemoglobin. Researchers zeroed in on the importance of LSD1 as a drug target after many years of research.
Then, they literally did a Google search to find drugs that act on LSD1. That’s how they found TCP, which since 1960 has been used to treat severe depression.
In the new paper, they describe how TCP blocks LSD1 and boosts the production of fetal hemoglobin—offsetting the devastating impact of the abnormal “adult” form of hemoglobin that sickle cell patients make.
“This is the first time that fetal hemoglobin synthesis was re-activated both in human blood cells and in mice to such a high level using a drug, and it demonstrates that once you understand the basic biological mechanism underlying a disease, you can develop drugs to treat it,” says Doug Engel, senior author of the study and chair of the Department of Cell & Developmental Biology at the University of Michigan.
“This grew out of an effort to discover the details of how hemoglobin is made during development, not with an immediate focus on curing sickle cell anemia, but just toward understanding it.”
Engel and colleagues have identified LSD1’s crucial role, and its epigenetic interaction with two nuclear receptors in the nuclei of red blood cell precursors called TR2 and TR4. Working in tandem, they repress the expression of the gene that makes fetal hemoglobin—an effect called gene silencing. So, interfering with this repression allows the fetal hemoglobin subunits to be made.
Treatment with TCP caused fetal hemoglobin to be produced at such high abundance that it made up 30 percent of all hemoglobin in cultured human blood cells—a finding Engel called “startling.” TCP is FDA-approved, though patients taking it need to follow strict dietary guidelines to avoid drug interactions with certain naturally occurring chemicals in some foods.
Boosting healthy hemoglobin
Sickle cell disease occurs when a person or animal inherits two defective copies of a gene that governs the production of the “adult” form of hemoglobin.
People with just one copy of the mutated gene normally do not get sick, but if they have a child with another person who carries the same trait, there is a one in four chance the child will develop the disease. An estimated 2.5 million Americans—including one in every 12 African Americans and one in every 100 Latinos—carry one copy of the mutated globin gene.
In sickle cell disease, the body makes a form of adult hemoglobin that can aggregate to cause red blood cells to become C-shaped or “sickle” shaped, and stiff and sticky. Those cells clog small blood vessels in the limbs and internal organs, causing organ damage and pain, raising the risk of infection. Life expectancy in these patients is greatly shortened.
In a very small number of sickle cell patients, the “fetal” form of hemoglobin—which is usually only made in the womb and the first couple of months of life—keeps being produced throughout life. These patients have symptoms that are either far less severe or nonexistent.
The most common current sickle cell treatment, oral hydroxyurea, aims to boost fetal hemoglobin production. Others, including transfusions and stem cell (bone marrow) transplants from unrelated donors, aim to exchange the source of the overall red blood cell supply.
Andrew Campbell, director of the Pediatric Comprehensive Sickle Cell program and has worked with Engel on previous research, says the new findings are exciting news for sickle cell patients, since there are not enough treatment options. But, he notes, more clinical research is needed to determine if the findings from mice and cultured human red cell precursors will translate to humans for TCP or even other drugs that inactivate LSD1.
The first such clinical trial is now being planned with the sickle cell team at Wayne State University in Detroit. Further information will be available later this year if it receives approval to go forward. At the same time, researchers are exploring other possible drug candidates targeting the same pathway.
Engel is working with psychiatrist Juan Lopez, to study the effect of TCP—and other antidepressants in the class known as monoamine oxidase inhibitors—on hemoglobin production in adults.
Researchers at Tohoku University in Japan contributed to the study that was funded by the National Institutes of Health and the American Heart Association.
Source: University of Michigan